Amylyx Prices Newly Approved ALS Drug at $158,000 Per Year

Amylyx Pharmaceuticals on Friday set the list price of its newly approved drug to treat amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States, a discount to its most recently approved competitor.
Reuters Health Information

source https://www.medscape.com/viewarticle/981708?src=rss